Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 03:17:51 2024-07-18 EDT			5-day change	1st Jan Change
1.06 ^HKD	+0.95%		+0.97%	-36.20%

07-10	Kintor Pharmaceutical Releases Anti-Hair Loss Product; Shares Up 8%	MT
07-10	Kintor Pharmaceutical Limited Announces Launch of Cosmetics with KX-826 as the Main Ingredient to Market	CI

Kintor Pharmaceutical Ltd announced that it has received CNY 288 million in funding from a group of investors

January 10, 2018

Kintor Pharmaceutical Ltd announced a private placement of CNY 288 million in its series C round of funding led by Shenzhen Green Pine Growth No. 1 Equity Investment Partnership Enterprise (L.P.), a fund managed by Shenzhen Green Pine International Capital Management Partnership Enterprise (L.P.) on January 11, 2018. The transaction included participation from Shanghai Orient Securities Capital Investment Co., Ltd., Hangzhou Beijia Investment Management Co., Ltd., Shanghai Broad Resources Investment Co., Ltd., CCBI Healthcare Fund; a fund managed by CCB International Asset Management Ltd. and existing investors HighLight Capital and Suzhou Oriza Holdings Co., Ltd.

Latest news about Kintor Pharmaceutical Limited

Kintor Pharmaceutical Releases Anti-Hair Loss Product; Shares Up 8%	07-09	MT
Kintor Pharmaceutical Limited Announces Launch of Cosmetics with KX-826 as the Main Ingredient to Market	07-09	CI
Kintor Pharmaceutical Limited Announces Retirement of Directors and Change in Composition of the Audit Committee	06-20	CI
Kintor Pharmaceutical Completed 1st Subject Enrolment in a Phase 2 Clinical Trial of Acne Drug in China	06-17	MT
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of GT20029 Gel for Treatment of Ance in China	06-17	CI
Kintor Pharma Receives Standard Cosmetic Ingredient Name for KX-826 Product	06-04	MT
Kintor Pharmaceutical Limited Announces Kx-826 Receives the Inci Designation	06-04	CI
Kintor Pharmaceutical's Androgenic Alopecia Drug Gets Regulatory Nod; Share Prices Shoot 10%	05-24	MT
Kintor Pharmaceutical Limited Announces That the Clinical Trial of Its In-House Developed and Potential First-In-Class Kx-826 Tincture 1.0% for the Treatment of Male Adult Androgenetic Alopecia ("Aga") in China (The "Clinical Trial") Was Cleared by the National Medical Products Administration (The "Nmpa") Recently	05-24	CI
Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	04-21	CI
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	04-21	MT
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator	02-01	MT
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA	02-01	CI
Kintor Pharmaceutical's Phase 3 Trial for Alopecia Treatment Promotes Hair Growth; Shares Plunge 30%	11-26	MT
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia	11-26	CI
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	23-10-11	CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Kintor Pharmaceutical Completes Enrollment for Alopecia Drug Trial	23-08-23	MT
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China	23-08-22	CI
Kintor Pharmaceutical Enrolls First Patient for Phase III of Alopecia Drug Trial	23-07-20	MT
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826	23-07-19	CI
Kintor Pharmaceutical Limited Appoints Ming Ming Cheung as Joint Company Secretary	23-05-12	CI
Kintor Pharmaceutical's Completes US Phase 2 Trials of Alopecia Treatment; Shares Fall 4%	23-05-12	MT
Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	23-05-11	CI

Chart Kintor Pharmaceutical Limited

Duration

Period

More charts

Company Profile

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9765 CNY

Average target price

13.17 CNY

Spread / Average Target

+1,249.05%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KINTOR PHARMACEUTICAL LIMITED	-36.20%	59.09M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.24%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.99%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs